Université de Bordeaux, INSERM, ARNA, 33076, Bordeaux, France.
Université Côte d'Azur, CNRS, ICN, 06107, Nice, France.
Sci Rep. 2018 Jan 26;8(1):1667. doi: 10.1038/s41598-018-20053-5.
MicroRNAs are key factors in the regulation of gene expression and their deregulation has been directly linked to various pathologies such as cancer. The use of small molecules to tackle the overexpression of oncogenic miRNAs has proved its efficacy and holds the promise for therapeutic applications. Here we describe the screening of a 640-compound library and the identification of polyamine derivatives interfering with in vitro Dicer-mediated processing of the oncogenic miR-372 precursor (pre-miR-372). The most active inhibitor is a spermine-amidine conjugate that binds to the pre-miR-372 with a K of 0.15 µM, and inhibits its in vitro processing with a IC of 1.06 µM. The inhibition of miR-372 biogenesis was confirmed in gastric cancer cells overexpressing miR-372 and a specific inhibition of proliferation through de-repression of the tumor suppressor LATS2 protein, a miR-372 target, was observed. This compound modifies the expression of a small set of miRNAs and its selective biological activity has been confirmed in patient-derived ex vivo cultures of gastric carcinoma. Polyamine derivatives are promising starting materials for future studies about the inhibition of oncogenic miRNAs and, to the best of our knowledge, this is the first report about the application of functionalized polyamines as miRNAs interfering agents.
微小 RNA 是基因表达调控的关键因素,其失调与各种病理学直接相关,如癌症。使用小分子来解决致癌 miRNA 的过度表达已被证明其疗效,并为治疗应用提供了希望。在这里,我们描述了对 640 种化合物库的筛选,并鉴定了干扰体外 Dicer 介导的致癌 miR-372 前体(pre-miR-372)加工的多胺衍生物。最活跃的抑制剂是一种 spermine-amidine 缀合物,它与 pre-miR-372 的结合 K 为 0.15 μM,并以 1.06 μM 的 IC 抑制其体外加工。在过表达 miR-372 的胃癌细胞中证实了 miR-372 生物发生的抑制,并且通过解除肿瘤抑制因子 LATS2 蛋白的抑制观察到了增殖的特异性抑制,LATS2 蛋白是 miR-372 的靶标。该化合物修饰了一小部分 miRNA 的表达,并且其选择性生物活性已在胃癌患者衍生的体外培养物中得到证实。多胺衍生物是未来关于抑制致癌 miRNA 的研究的有前途的起始材料,据我们所知,这是关于功能化多胺作为 miRNA 干扰剂的应用的第一个报告。